Status:
UNKNOWN
REduction of rIsk for Contrast Induced Nephropathy
Lead Sponsor:
Guangdong Provincial People's Hospital
Collaborating Sponsors:
First Affiliated Hospital, Sun Yat-Sen University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions:
Contrast Induced Nephropathy
Eligibility:
All Genders
18+ years
Brief Summary
The REduction of rIsk for Contrast-Induced Nephropathy (REICIN) study is the largest prospective multicenter data base for CIN flowing coronary angiography (CAG) or percutaneous coronary intervention ...
Detailed Description
This is a multicenter prospective observational study collecting data on over 5000 CAG patients admitted to department of cardiology in 12 hospitals from January 2013. Data will be collected for more ...
Eligibility Criteria
Inclusion
- Patients referred to CAG or PCI;
- Age ≥ 18 years
- Submit informed consent and adhere to the study protocol
Exclusion
- Fail to undergo CAG/PCI or die during the procedure；
- End-stage renal diseases or renal replacement；
- Pre-procedural unstable renal funciton (acute increase in serum creatinine more than 0.5mg/ml in the past 24 h)；
- Intravascular administration of a contrast medium within the previous 48 hours；
- Allergic to contrast medium;
- Pregnancy, lactation or malignant tumoror life expectancy\< 1 year;
- The use of renal toxicity drugs (non-steroidal anti-inflammatory drugs, aminoglycoside drugs, cyclosporine, cisplatin etc) within 48 h before cardiac catheter surgery and the whole process of the research;
- Refer to receive renal artery angiography or surgical valve replacement in patients with rheumatic heart disease； For exclusion creteria 7, patients admited and taked aspirin are included in the study.
Key Trial Info
Start Date :
January 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2018
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT01402232
Start Date
January 1 2013
End Date
November 1 2018
Last Update
August 3 2018
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaihong Chen
Longyan, Fujian, China
2
Guoliang Jia
Dongguan, Guangdong, China, 510000
3
Jianfeng Ye
Dongguan, Guangdong, China, 510000
4
Jian Qiu
Guangzhou, Guangdong, China, 510000